Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay

Summary: Peptide mobility shift assays provide a sensitive measure of kinase enzymatic activity and can be used to evaluate kinase inhibitors. Herein, we describe a protocol adapted for rapid assessment of doublecortin-like kinase inhibitors. Advantages include rapid iterations of therapeutic compou...

Full description

Bibliographic Details
Main Authors: Yan Liu, Kenneth D. Westover
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:STAR Protocols
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S266616672100294X
_version_ 1829502314314989568
author Yan Liu
Kenneth D. Westover
author_facet Yan Liu
Kenneth D. Westover
author_sort Yan Liu
collection DOAJ
description Summary: Peptide mobility shift assays provide a sensitive measure of kinase enzymatic activity and can be used to evaluate kinase inhibitors. Herein, we describe a protocol adapted for rapid assessment of doublecortin-like kinase inhibitors. Advantages include rapid iterations of therapeutic compound assessment and the ability to characterize kinase mutations, such as drug-resistant mutants for biological rescue experiments, on kinase activity.For complete details on the use and execution of this protocol, please refer to Liu et al. (2020).
first_indexed 2024-12-16T09:36:00Z
format Article
id doaj.art-9cb2921000cf45d5adecab4106b3f7fa
institution Directory Open Access Journal
issn 2666-1667
language English
last_indexed 2024-12-16T09:36:00Z
publishDate 2021-06-01
publisher Elsevier
record_format Article
series STAR Protocols
spelling doaj.art-9cb2921000cf45d5adecab4106b3f7fa2022-12-21T22:36:25ZengElsevierSTAR Protocols2666-16672021-06-0122100587Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assayYan Liu0Kenneth D. Westover1Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA; Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA; Corresponding authorDepartment of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA; Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA; Corresponding authorSummary: Peptide mobility shift assays provide a sensitive measure of kinase enzymatic activity and can be used to evaluate kinase inhibitors. Herein, we describe a protocol adapted for rapid assessment of doublecortin-like kinase inhibitors. Advantages include rapid iterations of therapeutic compound assessment and the ability to characterize kinase mutations, such as drug-resistant mutants for biological rescue experiments, on kinase activity.For complete details on the use and execution of this protocol, please refer to Liu et al. (2020).http://www.sciencedirect.com/science/article/pii/S266616672100294Xcancerhigh-throughput screeningmolecular/chemical probesprotein biochemistry
spellingShingle Yan Liu
Kenneth D. Westover
Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay
STAR Protocols
cancer
high-throughput screening
molecular/chemical probes
protein biochemistry
title Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay
title_full Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay
title_fullStr Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay
title_full_unstemmed Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay
title_short Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay
title_sort rapid assessment of dclk1 inhibitors using a peptide substrate mobility shift assay
topic cancer
high-throughput screening
molecular/chemical probes
protein biochemistry
url http://www.sciencedirect.com/science/article/pii/S266616672100294X
work_keys_str_mv AT yanliu rapidassessmentofdclk1inhibitorsusingapeptidesubstratemobilityshiftassay
AT kennethdwestover rapidassessmentofdclk1inhibitorsusingapeptidesubstratemobilityshiftassay